OTCPK:HTLZ.F

Stock Analysis Report

Executive Summary

Hamilton Thorne Ltd., together with its subsidiary, Hamilton Thorne, Inc., develops, manufactures, and sells precision laser devices and advanced image analysis systems for living cell applications in the fertility, stem cell, and developmental biology research markets.

Snowflake

Fundamentals

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Hamilton Thorne's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.3%

OTCPK:HTLZ.F

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

-11.4%

OTCPK:HTLZ.F

9.6%

US Medical Equipment

2.1%

US Market

HTLZ.F underperformed the Medical Equipment industry which returned 9.1% over the past year.

HTLZ.F underperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

HTLZ.FIndustryMarket
7 Day1.3%0.8%1.1%
30 Day-7.0%0.2%3.7%
90 Day-0.4%2.7%2.3%
1 Year-11.4%-11.4%10.5%9.6%4.4%2.1%
3 Year258.5%258.5%69.5%64.3%47.0%37.4%
5 Year697.7%697.7%132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is Hamilton Thorne's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hamilton Thorne undervalued based on future cash flows and its price relative to the stock market?

14%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Hamilton Thorne's share price is below the future cash flow value, but not at a moderate discount (< 20%).

Hamilton Thorne's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Hamilton Thorne is overvalued based on earnings compared to the US Medical Equipment industry average.

Hamilton Thorne is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Hamilton Thorne is good value based on expected growth next year.


Price Based on Value of Assets

Hamilton Thorne is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Hamilton Thorne expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

65.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Hamilton Thorne's revenue is expected to grow by 15.6% yearly, however this is not considered high growth (20% yearly).

Hamilton Thorne's earnings are expected to grow significantly at over 20% yearly.

Hamilton Thorne's revenue growth is expected to exceed the United States of America market average.

Hamilton Thorne's earnings growth is expected to exceed the United States of America market average.

Hamilton Thorne's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Hamilton Thorne will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Hamilton Thorne performed over the past 5 years?

37.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Hamilton Thorne has delivered over 20% year on year earnings growth in the past 5 years.

Hamilton Thorne's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Hamilton Thorne's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.


Return on Equity

Hamilton Thorne has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Hamilton Thorne used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Hamilton Thorne's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Hamilton Thorne's financial position?


Financial Position Analysis

Hamilton Thorne is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Hamilton Thorne's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Hamilton Thorne's level of debt (24.9%) compared to net worth is satisfactory (less than 40%).

Hamilton Thorne had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.

Debt is well covered by operating cash flow (53%, greater than 20% of total debt).

Interest payments on debt are not well covered by earnings (EBIT is 3x annual interest expense, ideally 3x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.5x debt.


Next Steps

Dividend

What is Hamilton Thorne's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Hamilton Thorne's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Hamilton Thorne's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Hamilton Thorne has not reported any payouts.

Unable to verify if Hamilton Thorne's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Hamilton Thorne has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Hamilton Thorne's salary, the management and board of directors tenure and is there insider trading?

8.8yrs

Average management tenure


CEO

David Wolf 0

8yrs

Tenure

US$467,275

Compensation

Mr. David B. Wolf has been the Chief Executive Officer of Hamilton Thorne Ltd. since September 2011 and serves as its President. Mr. Wolf has been a Director of Hamilton Thorne Ltd., since September 2011.  ...


CEO Compensation Analysis

David's remuneration is about average for companies of similar size in United States of America.

David's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

8.8yrs

Average Tenure

The average tenure for the Hamilton Thorne management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

9.9yrs

Average Tenure

67yo

Average Age

The tenure for the Hamilton Thorne board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$25,02212 Jun 19
Keith Edwards
EntityIndividual
Role
Senior Key Executive
Senior VP & GM
Shares31,250
Max PriceUS$0.81
SellUS$6,05407 Mar 19
Keith Edwards
EntityIndividual
Role
Senior Key Executive
Senior VP & GM
Shares7,750
Max PriceUS$0.78
SellUS$3,07105 Mar 19
Keith Edwards
EntityIndividual
Role
Senior Key Executive
Senior VP & GM
Shares3,900
Max PriceUS$0.79
SellUS$4,49004 Mar 19
Keith Edwards
EntityIndividual
Role
Senior Key Executive
Senior VP & GM
Shares5,700
Max PriceUS$0.79
SellUS$11,00410 Feb 19
Keith Edwards
EntityIndividual
Role
Senior Key Executive
Senior VP & GM
Shares13,900
Max PriceUS$0.79
BuyUS$23,39928 Nov 18
Keith Edwards
EntityIndividual
Role
Senior Key Executive
Senior VP & GM
Shares31,250
Max PriceUS$0.75

Ownership Breakdown


Management Team

  • Michael Bruns (62yo)

    VP of Finance & CFO

    • Tenure: 8.8yrs
    • Compensation: US$241.75k
  • Diarmaid Douglas-Hamilton

    Co-Founder

    • Tenure: 9.9yrs
    • Compensation: US$190.31k
  • Eric Dorman

    President of Embryotech Laboratories Inc

    • Tenure: 0yrs
    • Compensation: US$215.25k
  • Meg Spencer

    Co-Founder & Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$19.25k
  • David Wolf

    President

    • Tenure: 8yrs
    • Compensation: US$467.28k
  • Keith Edwards

    Senior VP & GM

    • Tenure: 3.8yrs
    • Compensation: US$171.70k
  • Fabian Sell

    Chief Executive Officer of Gynemed

    • Tenure: 0yrs
    • Compensation: US$259.40k

Board Members

  • Bob Potter (65yo)

    Director

    • Tenure: 9.9yrs
    • Compensation: US$26.50k
  • Daniel Thorne (67yo)

    Director

    • Tenure: 9.9yrs
    • Compensation: US$19.25k
  • Bruno Maruzzo (67yo)

    Director

    • Tenure: 12.5yrs
    • Compensation: US$29.75k
  • David Zhang

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Diarmaid Douglas-Hamilton

    Co-Founder

    • Tenure: 9.9yrs
    • Compensation: US$190.31k
  • Fred Kramer

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Alan Trounson (73yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Barbara Talamo

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Meg Spencer

    Co-Founder & Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$19.25k
  • David Wolf

    President

    • Tenure: 8yrs
    • Compensation: US$467.28k

Company Information

Hamilton Thorne Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hamilton Thorne Ltd.
  • Ticker: HTLZ.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$130.272m
  • Listing Market Cap: CA$98.319m
  • Shares outstanding: 125.26m
  • Website: https://www.hamiltonthorne.ltd

Location

  • Hamilton Thorne Ltd.
  • 100 Cummings Center
  • Suite 465E
  • Beverly
  • Massachusetts
  • 1915
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HTLTSXV (TSX Venture Exchange)YesCommon StockCACADNov 2009
HTLZ.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 2009
0ZMDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2009

Biography

Hamilton Thorne Ltd., together with its subsidiary, Hamilton Thorne, Inc., develops, manufactures, and sells precision laser devices and advanced image analysis systems for living cell applications in the  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 00:21
End of Day Share Price2019/09/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.